Letter: real-world use of terlipressin in patients with the hepatorenal syndrome-authors' reply
- PMID: 34236097
- DOI: 10.1111/apt.16486
Letter: real-world use of terlipressin in patients with the hepatorenal syndrome-authors' reply
Comment on
-
Real-world treatment patterns and outcomes using terlipressin in 203 patients with the hepatorenal syndrome.Aliment Pharmacol Ther. 2020 Jul;52(2):351-358. doi: 10.1111/apt.15836. Epub 2020 Jun 4. Aliment Pharmacol Ther. 2020. PMID: 32495956 Free PMC article.
-
Letter: real-world use of terlipressin in patients with hepatorenal syndrome.Aliment Pharmacol Ther. 2021 Aug;54(3):349. doi: 10.1111/apt.16449. Aliment Pharmacol Ther. 2021. PMID: 34236098 No abstract available.
References
REFERENCES
-
- Weng F. Letter: real-world use of terlipressin in patients with the hepatorenal syndrome. Aliment Pharmacol Ther. 2021;54:349.
-
- Mehtani R, De A, Singh V. Letter: HRS-AKI - a frequent misdiagnosis in the real-world setting? Aliment Pharmacol Ther. 2020;52:1090-1091.
-
- Moore K, Jamil K, Verleger K, et al. Real-world treatment patterns and outcomes using terlipressin in 203 patients with the hepatorenal syndrome. Aliment Pharmacol Ther. 2020;52:351-358.
-
- Wong F, Pappas SC, Boyer TD, et al. Terlipressin improves renal function and reverses hepatorenal syndrome in patients with systemic inflammatory response syndrome. Clin Gastroenterol Hepatol. 2017;15:266-272.e1.
-
- Trebicka J, Fernandez J, Papp M, et al. The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology. J Hepatol. 2020;73:842-854.